FDA Peptide Warning Letters (2026): The 11 Letters
[News · Enforcement]

FDA Peptide Warning Letters (2026): What the 11 Letters Show

11 letters to online peptide sellers · March 31, June 17 and August 24, 2026 · Counted November 11, 2026

Published · By Ethen Amezquita

Short answer: FDA's warning letter database shows 11 letters in 2026 to online sellers of peptides labeled for research: five dated March 31, one dated June 17 and five dated August 24. Ten of the 11 cited GLP-1 type products such as semaglutide, tirzepatide and retatrutide, often under code names like "GLP-3 RT," and nine listed bacteriostatic water itself as an unapproved new drug. Every letter quoted the seller's "research use only" or "not for human consumption" wording and said the website showed the products were drugs for human use. None of the 11 named BPC-157, TB-500 or the other peptides in the October 2026 HHS policy.

We searched FDA's warning letter database for "peptide" on November 11, 2026 and read every 2026 letter to a company selling peptides online. This page counts those letters and what they say. Company names are given because they appear in FDA's public letters; a warning letter is FDA's view, and the recipient may have responded since.

The 11 letters at a glance

Letter dateRecipient (links to FDA's letter)Products FDA named
March 31, 2026Lovega LLC dba Pink Pony Peptides"GLP-2 TZ," "GLP-3 RT," bacteriostatic water
March 31, 2026Gram PeptidesRetatrutide, tirzepatide, bacteriostatic water
March 31, 2026Prime SciencesCagrilintide, mazdutide, "GLP1-R," "GLP1-S," "GLP1-T," BAC water
March 31, 2026Mile High Compounds LLC"GLP-1 SM," "GLP-2 TRZ," "GLP-3 RT," BAC water
March 31, 2026PekCura Labs"GLP-1-S," "GLP-2-T," "GLP-3-R," bacteriostatic water
June 17, 2026Wholesale Peptide"Prostamax," gonadorelin
August 24, 2026Peak Performance PeptidesRetatrutide, semaglutide, SS-31, PT-141, tesamorelin, bac water
August 24, 2026Royal Peptides LLCTirzepatide, semaglutide, retatrutide, SS-31, PT-141, tesamorelin, "BIMORELIN"
August 24, 2026NuScience Peptides LLCTirzepatide, semaglutide, retatrutide, survodutide, mazdutide, PT-141, tesamorelin, a tesamorelin/ipamorelin blend, BAC water
August 24, 2026Peptide Partners LLCSemaglutide, tirzepatide, retatrutide, SS-31, tesamorelin, PT-141, "Reconstitution Solution (BAC)"
August 24, 2026TXP Innovations LLC dba Tex PeptidesSemaglutide, tirzepatide, retatrutide, SS-31, tesamorelin, PT-141, bacteriostatic water

All 11 came from the Office of Unapproved Drugs and Labeling Compliance in FDA's drug center (CDER). Each says the named products are unapproved new drugs, and that selling them across state lines violates sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act.

What the letters have in common

GLP-1 type drugs, often under code names

Ten of the 11 letters cite GLP-1 type products, either by name (semaglutide, tirzepatide, retatrutide) or under code names such as "GLP-1 SM," "GLP-2 TRZ" and "GLP-3 RT." Several also list newer weight-loss candidates: cagrilintide, mazdutide and survodutide. The one exception, the June 17 letter, covered "Prostamax" and gonadorelin.

The research label did not change the outcome

Every letter quotes the seller's own disclaimer, from "Research Use Only" to "in vitro research and educational purposes only." Each then says that, despite those statements, the evidence "establishes that your products are intended to be drugs for human use." The evidence FDA quotes is the sellers' own claims about weight loss, blood sugar, appetite and similar effects. Our post on what research use only means explains the law behind this.

Bacteriostatic water counted as a drug

Nine letters list the seller's bacteriostatic water as an unapproved new drug in its own right. FDA's reasoning, in the March 31 letter to Gram Peptides, is that selling it "alongside peptide products, which are drugs intended for injection and require reconstitution" shows it is meant for injection. The Prime Sciences letter cites a "Reconstitution Kit" that paired the water with a syringe. Two August letters add that the seller offered the water next to a "peptide calculator" (and in one case a "peptide guide"), which FDA called resources that provide "the means to prepare an injectable drug for human administration."

A short clock

The five March letters ask for a written reply within fifteen working days; the June and August letters say fifteen business days. Each warns that failing to fix the problems may lead to action "including, without limitation, seizure and injunction."

What the letters did not cover

We searched all 11 letters for BPC-157, TB-500, thymosin, GHK-Cu, MOTS-c, KPV, semax and epitalon. None appears. In 2026, at least in these posted letters, FDA focused on GLP-1 type drugs and a handful of others (SS-31, PT-141, tesamorelin, gonadorelin), not on the peptides its advisory committee reviewed in July. That is a description of what was posted, not a statement that other peptides are allowed. Those six are still not on the 503A bulks list, and the HHS policy covers only pharmacy compounding with a prescription.

FDA's 2026 letters also include cases outside online "research" shops. A May 1, 2026 letter to Harbin Jixianglong Biotech concerns manufacturing (CGMP) problems at a maker of peptide ingredients, including GLP-1 ingredients. We did not count it among the 11 because it went to an ingredient maker, not a seller of finished "research" products.

Why it matters if you use these products

  • Products named in these letters were not made under FDA oversight. FDA's letters stress that injected products "bypass some of the body's key defenses against toxins and microorganisms."
  • For GLP-1 medicines, FDA-approved versions exist. Talk to your clinician about options; see our semaglutide vs tirzepatide comparison and what retatrutide's trials showed.
  • If you have a problem after using any product, you can report it to FDA MedWatch.
  • Keep the label, lot number and any certificate of analysis for anything you inject. Our COA guide explains what those papers can and cannot tell you.

Frequently asked questions

How many FDA warning letters went to peptide sellers in 2026?+
Eleven letters to online sellers of research peptides were posted in FDA's warning letter database as of November 11, 2026: five dated March 31, one dated June 17 and five dated August 24, 2026.
Does a research use only label protect a peptide seller from FDA?+
Not according to these letters. All 11 quoted the seller's research or not-for-human-use wording and said the websites showed the products were intended as drugs for human use.
Why did FDA call bacteriostatic water a drug?+
FDA said that selling bacteriostatic water next to peptides that need reconstitution for injection shows it is meant to be injected with them. Nine of the 11 letters listed the seller's bacteriostatic water as an unapproved new drug.
Did the 2026 FDA warning letters name BPC-157 or TB-500?+
No. We searched all 11 letters for BPC-157, TB-500, thymosin, GHK-Cu, MOTS-c, KPV, semax and epitalon and found none. Ten letters cited GLP-1 type products such as semaglutide, tirzepatide and retatrutide, by name or code name.
What happens after an FDA warning letter?+
The letters ask for a written reply within fifteen working or business days and warn that failing to fix the violations may lead to action including seizure and injunction. A recipient may respond, and FDA may later post a response or close-out letter.

Sources

Every fact in this article comes from FDA's own warning letters, read in full on November 11, 2026. This article is for education. It is not medical or legal advice.

  1. U.S. Food and Drug Administration. Warning Letters database (search: "peptide"; content current as of November 10, 2026). fda.gov
  2. U.S. Food and Drug Administration. Warning letter to Lovega LLC dba Pink Pony Peptides, MARCS-CMS 721088, March 31, 2026. fda.gov
  3. U.S. Food and Drug Administration. Warning letter to Gram Peptides, MARCS-CMS 721806, March 31, 2026. fda.gov
  4. U.S. Food and Drug Administration. Warning letter to Prime Sciences, MARCS-CMS 721805, March 31, 2026. fda.gov
  5. U.S. Food and Drug Administration. Warning letter to Mile High Compounds LLC, MARCS-CMS 721600, March 31, 2026. fda.gov
  6. U.S. Food and Drug Administration. Warning letter to PekCura Labs, MARCS-CMS 721709, March 31, 2026. fda.gov
  7. U.S. Food and Drug Administration. Warning letter to Wholesale Peptide, MARCS-CMS 729447, June 17, 2026. fda.gov
  8. U.S. Food and Drug Administration. Warning letter to Peak Performance Peptides, MARCS-CMS 735127, August 24, 2026. fda.gov
  9. U.S. Food and Drug Administration. Warning letter to Royal Peptides LLC, MARCS-CMS 734884, August 24, 2026. fda.gov
  10. U.S. Food and Drug Administration. Warning letter to NuScience Peptides LLC, MARCS-CMS 733652, August 24, 2026. fda.gov
  11. U.S. Food and Drug Administration. Warning letter to Peptide Partners LLC, MARCS-CMS 735063, August 24, 2026. fda.gov
  12. U.S. Food and Drug Administration. Warning letter to TXP Innovations LLC dba Tex Peptides, MARCS-CMS 735067, August 24, 2026. fda.gov
  13. U.S. Food and Drug Administration. Warning letter to Harbin Jixianglong Biotech Co., Ltd., MARCS-CMS 723330, May 1, 2026. fda.gov